Published in Oncologist on October 01, 2007
Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA (2012) 2.56
Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol (2009) 1.80
The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review. PLoS One (2013) 1.20
M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. PLoS One (2008) 1.11
Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer. Onco Targets Ther (2013) 1.04
Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress? J Thorac Dis (2011) 0.95
Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design. J Pers Med (2014) 0.92
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. Exp Biol Med (Maywood) (2010) 0.84
Transgenic expression of VEGF in intestinal epithelium drives mesenchymal cell interactions and epithelial neoplasia. Gastroenterology (2008) 0.83
Tumors as organs: biologically augmenting radiation therapy by inhibiting transforming growth factor β activity in carcinomas. Semin Radiat Oncol (2013) 0.83
Assessement of angiogenesis reveals blood vessel heterogeneity in lung carcinoma. Oncol Lett (2012) 0.79
Targeted medical therapy of biliary tract cancer: recent advances and future perspectives. World J Gastroenterol (2008) 0.77
Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment. Am J Cancer Res (2016) 0.76
Systemic bevacizumab for simultaneous treatment of cancer and choroidal neovascularisation. BMJ Case Rep (2014) 0.75
Vandetanib in advanced non small cell lung cancer: a promise unfulfilled. Transl Lung Cancer Res (2013) 0.75
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol (2004) 12.89
Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol (2008) 3.95
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst (2003) 3.41
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 3.13
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol (2012) 3.04
NF-kappaB and virus infection: who controls whom. EMBO J (2003) 2.08
Unanswered questions: monoclonal antibodies in the treatment of advanced non-small-cell lung cancer. Oncology (Williston Park) (2010) 2.06
Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene (2003) 1.88
Compliance with therapy in hypertensive patients. Intern Emerg Med (2006) 1.66
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol (2007) 1.60
Transcription of Satellite III non-coding RNAs is a general stress response in human cells. Nucleic Acids Res (2007) 1.58
Comparative genome analysis of Trichophyton rubrum and related dermatophytes reveals candidate genes involved in infection. MBio (2012) 1.55
Treating advanced non-small cell lung cancer in the elderly. Ther Adv Med Oncol (2010) 1.53
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer (2003) 1.44
A diastrophic dysplasia sulfate transporter (SLC26A2) mutant mouse: morphological and biochemical characterization of the resulting chondrodysplasia phenotype. Hum Mol Genet (2005) 1.43
The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist (2008) 1.39
Treatment of pulmonary neuroendocrine tumours: state of the art and future developments. Cancer Treat Rev (2012) 1.37
Collagen plays an active role in the aggregation of beta2-microglobulin under physiopathological conditions of dialysis-related amyloidosis. J Biol Chem (2006) 1.33
Treatment of advanced non small cell lung cancer. J Thorac Dis (2011) 1.32
Proinflammatory cytokines and cardiac abnormalities in uncomplicated obesity: relationship with abdominal fat deposition. Nutr Metab Cardiovasc Dis (2006) 1.27
Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori (2007) 1.27
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther (2013) 1.26
Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist (2007) 1.26
Recent developments of targeted therapies in the treatment of non-small cell lung cancer. Curr Drug Discov Technol (2009) 1.26
Dermatophytes: host-pathogen interaction and antifungal resistance. An Bras Dermatol (2010) 1.23
Herpes simplex virus disrupts NF-kappaB regulation by blocking its recruitment on the IkappaBalpha promoter and directing the factor on viral genes. J Biol Chem (2006) 1.22
Heparin strongly enhances the formation of beta2-microglobulin amyloid fibrils in the presence of type I collagen. J Biol Chem (2007) 1.18
Phenotypic features of carbohydrate sulfotransferase 3 (CHST3) deficiency in 24 patients: congenital dislocations and vertebral changes as principal diagnostic features. Am J Med Genet A (2010) 1.17
Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol (2005) 1.16
Congenital joint dislocations caused by carbohydrate sulfotransferase 3 deficiency in recessive Larsen syndrome and humero-spinal dysostosis. Am J Hum Genet (2008) 1.15
Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist (2007) 1.14
The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. J Thorac Oncol (2009) 1.13
Chondrodysplasia and abnormal joint development associated with mutations in IMPAD1, encoding the Golgi-resident nucleotide phosphatase, gPAPP. Am J Hum Genet (2011) 1.12
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer (2009) 1.11
Antifungal resistance mechanisms in dermatophytes. Mycopathologia (2008) 1.10
Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis (2010) 1.09
Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. J Thorac Oncol (2007) 1.07
Treatment of advanced non-small-cell lung cancer in the elderly. Lung Cancer (2009) 1.07
Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer (2009) 1.07
Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene (2003) 1.06
Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist (2009) 1.05
Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. Lung Cancer (2010) 1.03
ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Target Oncol (2013) 1.02
Differential expression of both extracellular and intracellular proteins is involved in the lethal or nonlethal phenotypic variation of BrtlIV, a murine model for osteogenesis imperfecta. Proteomics (2007) 1.01
Interaction of decorin with CNBr peptides from collagens I and II. Evidence for multiple binding sites and essential lysyl residues in collagen. Eur J Biochem (2002) 1.01
Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy. Stem Cells (2012) 1.00
Lung cancer in the elderly. J Clin Oncol (2007) 1.00
Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol (2007) 0.99
Molecular diagnosis of analbuminemia: a novel mutation identified in two Amerindian and two Turkish families. Clin Chem (2002) 0.99
Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line? Oncologist (2009) 0.99
Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. Sci Rep (2015) 0.99
Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Oncologist (2009) 0.97
The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol (2008) 0.96
The pH signaling transcription factor PacC mediates the growth of Trichophyton rubrum on human nail in vitro. Med Mycol (2006) 0.94
Beta2-microglobulin isoforms display an heterogeneous affinity for type I collagen. Protein Sci (2005) 0.94
Medical treatment of small cell lung cancer: state of the art and new development. Expert Opin Pharmacother (2013) 0.94
Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. J Thorac Oncol (2007) 0.93
Defective proteoglycan sulfation of the growth plate zones causes reduced chondrocyte proliferation via an altered Indian hedgehog signalling. Matrix Biol (2010) 0.92
Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel. Crit Rev Oncol Hematol (2007) 0.92
A novel splicing mutation causes an undescribed type of analbuminemia. Biochim Biophys Acta (2002) 0.90
Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer? Lung Cancer (2009) 0.90
Positron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC). J Exp Clin Cancer Res (2008) 0.90
Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Anticancer Res (2009) 0.90
Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study. Lung Cancer (2013) 0.90
Further delineation of CANT1 phenotypic spectrum and demonstration of its role in proteoglycan synthesis. Hum Mutat (2012) 0.89
Treatment of small cell lung cancer in the elderly. Oncologist (2005) 0.89
A transcript finishing initiative for closing gaps in the human transcriptome. Genome Res (2004) 0.89
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer (2010) 0.88
Self-aggregation of fibrillar collagens I and II involves lysine side chains. Micron (2006) 0.88
EURTAC first-line phase III randomized study in advanced non-small cell lung cancer: Erlotinib works also in European population. J Thorac Dis (2012) 0.88
Erlotinib in the treatment of non-small cell lung cancer: current status and future developments. Anticancer Res (2010) 0.88
The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Investig Drugs (2010) 0.88
Identification of EGFR mutations in lung sarcomatoid carcinoma. Int J Cancer (2011) 0.88
Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases. Lung Cancer (2005) 0.88